Published in Mol Psychiatry on April 30, 2013
Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener (2016) 1.41
Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol (2014) 0.98
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement (2014) 0.89
Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep (2016) 0.86
Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimers Dement (Amst) (2015) 0.86
Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. Front Neurol (2015) 0.81
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther (2015) 0.81
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement (2016) 0.80
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis (2015) 0.78
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry (2016) 0.77
Towards Personalized Intervention for Alzheimer's Disease. Genomics Proteomics Bioinformatics (2016) 0.76
Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimers Dement (Amst) (2017) 0.75
Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele. Front Aging Neurosci (2015) 0.75
Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease. J Alzheimers Dis (2015) 0.75
Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75
Imago Mundi, Imago AD, Imago ADNI. Alzheimers Res Ther (2014) 0.75
Alzheimer's disease: are blood and brain markers related? A systematic review. Ann Clin Transl Neurol (2016) 0.75
A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. J Alzheimers Dis (2015) 0.75
A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. J Alzheimers Dis (2017) 0.75
Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan. Alzheimers Dement (Amst) (2017) 0.75
Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. Brain Behav Immun (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage (2002) 49.90
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res (1990) 14.82
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology (1997) 3.04
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res (2011) 2.97
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 2.66
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 2.44
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol (2010) 2.42
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology (2010) 1.99
Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol (1999) 1.96
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology (2008) 1.71
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One (2011) 1.55
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett (2001) 1.44
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology (2011) 1.37
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem (2006) 1.16
Plasma ß-amyloid and cognitive decline. Arch Neurol (2010) 1.13
Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis (2010) 1.10
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci (2010) 1.05
Minireview: Gut peptides regulating satiety. Endocrinology (2004) 0.99
A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab (2005) 0.92
Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis (2010) 0.86
Elevated levels of circulating pancreatic polypeptide in inflammatory and infectious disorders. Regul Pept (1980) 0.83
Human pancreatic polypeptide has a marked diurnal rhythm that is affected by ageing and is associated with the gastric TFF2 circadian rhythm. Peptides (2005) 0.82
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA (2017) 2.58
Common genetic variants influence human subcortical brain structures. Nature (2015) 2.40
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav (2012) 1.97
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal (2013) 1.85
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol (2016) 1.76
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One (2013) 1.47
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Whole-brain analysis reveals increased neuroanatomical asymmetries in dementia for hippocampus and amygdala. Brain (2016) 1.40
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature (2017) 1.39
APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry (2013) 1.37
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol (2012) 1.33
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys (2010) 1.28
Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement (2012) 1.27
Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2011) 1.27
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Simultaneous multi-scale registration using large deformation diffeomorphic metric mapping. IEEE Trans Med Imaging (2011) 1.23
A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis (2011) 1.20
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging (2014) 1.17
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement (2012) 1.16
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct (2013) 1.16
Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurol (2016) 1.15
aBEAT: a toolbox for consistent analysis of longitudinal adult brain MRI. PLoS One (2013) 1.13
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol (2011) 1.13
Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci (2012) 1.10
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Cortical surface reconstruction via unified Reeb analysis of geometric and topological outliers in magnetic resonance images. IEEE Trans Med Imaging (2013) 1.04
Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc (2014) 1.04
Using manifold learning for atlas selection in multi-atlas segmentation. PLoS One (2013) 1.04
Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav (2012) 1.03
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry (2014) 1.02
Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement (2012) 1.01
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun (2014) 1.01
Transcriptome-guided amyloid imaging genetic analysis via a novel structured sparse learning algorithm. Bioinformatics (2014) 1.01
A sparse structure learning algorithm for Gaussian Bayesian Network identification from high-dimensional data. IEEE Trans Pattern Anal Mach Intell (2013) 1.00
Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging Behav (2012) 0.99
Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med (2015) 0.99
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain (2016) 0.99
The perfect neuroimaging-genetics-computation storm: collision of petabytes of data, millions of hardware devices and thousands of software tools. Brain Imaging Behav (2014) 0.97
Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Mol Psychiatry (2013) 0.97
Cascading network failure across the Alzheimer's disease spectrum. Brain (2015) 0.97
The role of visualization and 3-D printing in biological data mining. BioData Min (2015) 0.96
α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2013) 0.96
A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain (2014) 0.96
Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One (2013) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr (2015) 0.96
Confirmatory factor analysis of the ADNI Neuropsychological Battery. Brain Imaging Behav (2012) 0.95
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
A novel relational regularization feature selection method for joint regression and classification in AD diagnosis. Med Image Anal (2015) 0.92
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
Clinical prediction from structural brain MRI scans: a large-scale empirical study. Neuroinformatics (2015) 0.92
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord (2013) 0.92
Models of the aging brain structure and individual decline. Front Neuroinform (2012) 0.91
Sparse temporally dynamic resting-state functional connectivity networks for early MCI identification. Brain Imaging Behav (2016) 0.91
Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord (2012) 0.91
Effect of cognitive reserve markers on Alzheimer pathologic progression. Alzheimer Dis Assoc Disord (2013) 0.91
Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes (2015) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav (2012) 0.90
Toward a dynamic biomarker model in Alzheimer's disease. J Alzheimers Dis (2012) 0.90
Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav (2013) 0.89
Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. Med Image Anal (2013) 0.89
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. J Alzheimers Dis (2015) 0.89
Nonlinear dimensionality reduction combining MR imaging with non-imaging information. Med Image Anal (2011) 0.88
Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One (2013) 0.88
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol (2016) 0.87
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration. Mol Neurodegener (2013) 0.87
Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PLoS One (2013) 0.87
Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging Behav (2014) 0.87
Genetic architecture of resilience of executive functioning. Brain Imaging Behav (2012) 0.87
Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol (2014) 0.87
Risk classification in mild cognitive impairment patients for developing Alzheimer's disease. J Alzheimers Dis (2012) 0.87
The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol (2015) 0.87
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol (2015) 0.87
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
Changes in thalamic connectivity in the early and late stages of amnestic mild cognitive impairment: a resting-state functional magnetic resonance study from ADNI. PLoS One (2015) 0.86
Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport (2013) 0.86
ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry (2013) 0.86
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res (2014) 0.86
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85
NMF-SVM based CAD tool applied to functional brain images for the diagnosis of Alzheimer's disease. IEEE Trans Med Imaging (2011) 0.85
Multiple instance learning for classification of dementia in brain MRI. Med Image Anal (2014) 0.85